AMGN240802C330000
- 5.49
- -1.65-23.11%
Amgen Newsroom
Wall Street Is Still Jittery on GLP-1s
Should We Be Delighted With Amgen Inc.'s (NASDAQ:AMGN) ROE Of 75%?
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 59% Above Its Share Price
Unpacking the Latest Options Trading Trends in Amgen
Amgen (AMGN) Stock Moves -0.39%: What You Should Know
Here's What To Do Next After the Big Stock Market Slide
Market Whales and Their Recent Bets on AMGN Options
IBM, Amgen Share Gains Lead Dow's Nearly 175-Point Climb
Amgen Inc. Reaches All-time High at $339.19, Marking a Significant Milestone
The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
What Lies in Store for Healthcare ETFs in Q2 Earnings?
Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Investors in Amgen (NASDAQ:AMGN) Have Seen Splendid Returns of 122% Over the Past Five Years
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Here Are Big Pharma's Leading Blockbuster Makers
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note